Search

Your search keyword '"Itabashi, Megumi"' showing total 19 results
Start Over Author "Itabashi, Megumi"
19 results on '"Itabashi, Megumi"'

1. Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy

Author

Nakajima, Yuki, Tomita, Naoto, Itabashi, Megumi, Miyashita, Kazuho, Watanabe, Reina, Miyazaki, Takuya, Tachibana, Takayoshi, Takasaki, Hirotaka, Kawasaki, Rika, Tanaka, Masatsugu, Hashimoto, Chizuko, Yamazaki, Etsuko, Taguchi, Jun, Fujimaki, Katsumichi, Sakai, Rika, Fujita, Hiroyuki, Fujisawa, Shin, Harano, Hiroshi, Motomura, Shigeki, and Ishigatsubo, Yoshiaki

Published
2015
Full Text
View/download PDF

2. Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy

Author

Nakajima, Yuki, Tomita, Naoto, Watanabe, Reina, Ishiyama, Yasufumi, Yamamoto, Eri, Ishibashi, Daisuke, Itabashi, Megumi, Koyama, Satoshi, Takahashi, Hiroyuki, Numata, Ayumi, Takasaki, Hirotaka, Kawasaki, Rika, Kuwabara, Hideyuki, Tanaka, Masatsugu, Hashimoto, Chizuko, Fujimaki, Katsumichi, Sakai, Rika, Motomura, Shigeki, and Ishigatsubo, Yoshiaki

Published
2014
Full Text
View/download PDF

4. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era

Author

Watanabe, Reina, Tomita, Naoto, Itabashi, Megumi, Ishibashi, Daisuke, Yamamoto, Eri, Koyama, Satoshi, Miyashita, Kazuho, Takahashi, Hiroyuki, Nakajima, Yuki, Hattori, Yukako, Motohashi, Kenji, Takasaki, Hirotaka, Ohshima, Rika, Hashimoto, Chizuko, Yamazaki, Etsuko, Fujimaki, Katsumichi, Sakai, Rika, Fujisawa, Shin, Motomura, Shigeki, and Ishigatsubo, Yoshiaki

Published
2014
Full Text
View/download PDF

5. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients

Author

Yamamoto, Eri, Fujisawa, Shin, Hagihara, Maki, Tanaka, Masatsugu, Fujimaki, Katsumichi, Kishimoto, Kumiko, Hashimoto, Chizuko, Itabashi, Megumi, Ishibashi, Daisuke, Nakajima, Yuki, Tachibana, Takayoshi, Kawasaki, Rika, Kuwabara, Hideyuki, Koharazawa, Hideyuki, Yamazaki, Etsuko, Tomita, Naoto, Sakai, Rika, Fujita, Hiroyuki, Kanamori, Heiwa, and Ishigatsubo, Yoshiaki

Published
2014
Full Text
View/download PDF

6. Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia

Author

Yamazaki, Etsuko, primary, Kanamori, Heiwa, additional, Itabashi, Megumi, additional, Ogusa, Eriko, additional, Numata, Ayumi, additional, Yamamoto, Wataru, additional, Ito, Satomi, additional, Tachibana, Takayoshi, additional, Hagihara, Maki, additional, Matsumoto, Kenji, additional, Koharazawa, Hideyuki, additional, Taguchi, Jun, additional, Tomita, Naoto, additional, Fujimaki, Katsumichi, additional, Fujita, Hiroyuki, additional, Fujisawa, Shin, additional, Ogawa, Koji, additional, and Ishigatsubo, Yoshiaki, additional

Published
2016
Full Text
View/download PDF

8. Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis

Author

Yamamoto, Wataru, primary, Andou, Taiki, additional, Itabashi, Megumi, additional, Koyama, Satoshi, additional, Ishii, Yoshimi, additional, Numata, Ayumi, additional, Motohashi, Kenji, additional, Hagihara, Maki, additional, Matsumoto, Kenji, additional, and Fujisawa, Shin, additional

Published
2016
Full Text
View/download PDF

10. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation

Author

Numata, Ayumi, primary, Kajiyama, Ryoko, additional, Itabashi, Megumi, additional, Ishii, Yoshimi, additional, Yamamoto, Wataru, additional, Motohashi, Kenji, additional, Matsumoto, Kenji, additional, Hagihara, Maki, additional, Ishigatsubo, Yoshiaki, additional, and Fujisawa, Shin, additional

Published
2015
Full Text
View/download PDF

11. No Outcome Differences Were Observed Between Supra-Diaphragmatic and Infra-Diaphragmatic Lesions in Limited-Stage Diffuse Large B Cell Lymphoma Treated with R-CHOP Therapy, Whereas the Presence of Gastro-Intestinal Lesions Was Associated with a Favorable Prognosis

Author

Nakajima, Yuki, primary, Tomita, Naoto, additional, Itabashi, Megumi, additional, Miyashita, Kazuho, additional, Watanabe, Reina, additional, Miyazaki, Takuya, additional, Tachibana, Takayoshi, additional, Takasaki, Hirotaka, additional, Kawasaki, Rika, additional, Tanaka, Masatsugu, additional, Hashimoto, Chizuko, additional, Yamazaki, Etsuko, additional, Taguchi, Jun, additional, Fujimaki, Katsumichi, additional, Sakai, Rika, additional, Fujita, Hiroyuki, additional, Fujisawa, Shin, additional, Harano, Hiroshi, additional, Motomura, Shigeki, additional, and Ishigatsubo, Yoshiaki, additional

Published
2014
Full Text
View/download PDF

12. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B‐cell lymphoma in the rituximab era

Author

Watanabe, Reina, primary, Tomita, Naoto, additional, Itabashi, Megumi, additional, Ishibashi, Daisuke, additional, Yamamoto, Eri, additional, Koyama, Satoshi, additional, Miyashita, Kazuho, additional, Takahashi, Hiroyuki, additional, Nakajima, Yuki, additional, Hattori, Yukako, additional, Motohashi, Kenji, additional, Takasaki, Hirotaka, additional, Ohshima, Rika, additional, Hashimoto, Chizuko, additional, Yamazaki, Etsuko, additional, Fujimaki, Katsumichi, additional, Sakai, Rika, additional, Fujisawa, Shin, additional, Motomura, Shigeki, additional, and Ishigatsubo, Yoshiaki, additional

Published
2013
Full Text
View/download PDF

13. Hyper-Recovery Of Platelet After Induction Therapy Is a Significant Predictor For Relapse In Acute Myeloid Leukemia

Author

Yamazaki, Etsuko, primary, Itabashi, Megumi, additional, Eriko, Ogusa, additional, Numata, Ayumi, additional, Yamamoto, Wataru, additional, Ito, Satomi, additional, Miyazaki, Takuya, additional, Tachibana, Takayoshi, additional, Kuwabara, Hideyuki, additional, Hagihara, Maki, additional, Matsumoto, Kenji, additional, Koharazawa, Hideyuki, additional, Taguchi, Jun, additional, Tomita, Naoto, additional, Fujimaki, Katsumichi, additional, Fujita, Hiroyuki, additional, Fujisawa, Shin, additional, Kanamori, Heiwa, additional, Ogawa, Koji, additional, and Ishigatsubo, Yoshiaki, additional

Published
2013
Full Text
View/download PDF

14. Serum Beta-2 Microglobulin Level As a Useful Prognostic Marker Of Hodgkin Lymphoma

Author

Nakajima, Yuki, primary, Tomita, Naoto, additional, Watanabe, Reina, additional, Ishiyama, Yasufumi, additional, Yamamoto, Eri, additional, Ishibashi, Daisuke, additional, Itabashi, Megumi, additional, Koyama, Satoshi, additional, Takahashi, Hiroyuki, additional, Numata, Ayumi, additional, Takasaki, Hirotaka, additional, Kawasaki, Rika, additional, Kuwabara, Hideyuki, additional, Tanaka, Masatsugu, additional, Hashimoto, Chizuko, additional, Fujimaki, Katsumichi, additional, Sakai, Rika, additional, Motomura, Shigeki, additional, and Ishigatsubo, Yoshiaki, additional

Published
2013
Full Text
View/download PDF

15. Serum Ferritin Level As a Prognostic Marker For Peripheral T-Cell Lymphoma.

Author

Koyama, Satoshi, primary, Tomita, Naoto, additional, Watanabe, Reina, additional, Itabashi, Megumi, additional, Ishibashi, Daisuke, additional, Ishii, Yoshimi, additional, Hattori, Yukako, additional, Nakajima, Yuki, additional, Motohashi, Kenji, additional, Takasaki, Hirotaka, additional, Kawasaki, Rika, additional, Hashimoto, Chizuko, additional, Koharazawa, Hideyuki, additional, Takemura, Sachiya, additional, Sakai, Rika, additional, Fujisawa, Shin, additional, Motomura, Shigeki, additional, and Ishigatsubo, Yoshiaki, additional

Published
2013
Full Text
View/download PDF

16. Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.

Author

Yamazaki, Etsuko, Kanamori, Heiwa, Itabashi, Megumi, Ogusa, Eriko, Numata, Ayumi, Yamamoto, Wataru, Ito, Satomi, Tachibana, Takayoshi, Hagihara, Maki, Matsumoto, Kenji, Koharazawa, Hideyuki, Taguchi, Jun, Tomita, Naoto, Fujimaki, Katsumichi, Fujita, Hiroyuki, Fujisawa, Shin, Ogawa, Koji, and Ishigatsubo, Yoshiaki

Subjects
ACUTE myeloid leukemia treatment, CANCER relapse, BLOOD platelets, REGENERATION (Biology), HEMATOPOIESIS, CANCER chemotherapy
Abstract

We verified the association between standard clinical and laboratory variables and the risk of relapse in acute myeloid leukemia (AML), which led us to retrospectively examine the effect of regeneration of hematopoiesis in patients with newly diagnosed AML. We used data from 230 patients who obtained remission after cytarabine-based induction chemotherapy. Platelet counts ≥500 × 109/L and hemoglobin levels ≥9 g/dL on day 28 after treatment initiation were significantly associated with relapse-free survival (RFS) rate, conferring respective multivariate risk ratios of 0.38 (95% CI: 0.18–0.79) and 0.60 (95% CI: 0.40–0.89) for the occurrence of relapse or death. No disease relapse occurred in core binding factor leukemia patients whose platelet counts recovered ≥500 × 109/L at 28 days after therapy initiation. We conclude that regeneration of hematopoiesis, especially platelet hyper-recovery, after induction chemotherapy is a significant predictor of RFS in patients with AML. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

17. Musculoskeletal pain may be associated with imatinib withdrawal syndrome in chronic myeloid leukemia patients.

Author

Ishii, Yoshimi, Hagihara, Maki, Kato, Ai, Ando, Taiki, Itabashi, Megumi, Koyama, Satoshi, Yamamoto, Wataru, Motohashi, Kenji, Matsumoto, Kenji, and Fujisawa, Shin

Subjects
IMATINIB, MYELOID leukemia, MUSCULOSKELETAL system diseases, SHOULDER pain, ANTI-inflammatory agents, CREATINE kinase, C-reactive protein, PATIENTS, THERAPEUTICS
Abstract

The article reports on imatinib withdrawal syndrome in chronic myeloid leukemia (CML) patients can be associated with musculoskeletal pain. It states that pain was localized to various parts of the body, especially the limbs and shoulders and non-steroidal anti-inflammatory drugs, creatine kinase (CK) and C-reactive protein (CRP) were administered. It mentions that none of the patients developed additional symptoms after stopping imatinib and symptoms of the patients were very similar.

Published
2016
Full Text
View/download PDF

18. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.

Author

Numata, Ayumi, Kajiyama, Ryoko, Itabashi, Megumi, Ishii, Yoshimi, Yamamoto, Wataru, Motohashi, Kenji, Matsumoto, Kenji, Hagihara, Maki, Ishigatsubo, Yoshiaki, and Fujisawa, Shin

Subjects
HUMAN cytogenetics, IMATINIB, TREATMENT of chronic myeloid leukemia
Abstract

A letter to the editor is presented which discusses a case study of a 29-year-old Japanese woman who developed del(20q) cytogenetic abnormality during imatinib treatment for chronic myelogeneous leukemia (CML).

Published
2016
Full Text
View/download PDF

19. Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia.

Author

Morishita S, Hagihara M, Itabashi M, Ishii Y, Yamamoto W, Numata A, Motohashi K, Matsumoto K, Fujisawa S, and Nakajima H

Subjects
Administration, Oral, Adult, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Dasatinib administration & dosage, Dasatinib therapeutic use, Fatal Outcome, Female, Humans, Hypertension, Pulmonary diagnostic imaging, Antineoplastic Agents adverse effects, Dasatinib adverse effects, Hypertension, Pulmonary chemically induced, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Pulmonary Artery diagnostic imaging
Abstract

We present a 36-year-old woman who had been taking oral dasatinib for 3 years for the treatment of chronic myelogenous leukemia (CML). Although adverse events such as thrombocytopenia and pleural effusion developed, she showed a major molecular response (MMR) 22 months after the initiation of oral dasatinib administration, and the therapy was thus continued. Approximately 34 months after oral dasatinib initiation, she developed severe exertional dyspnea and had to be urgently hospitalized. There was no apparent pleural effusion increase, and neither imaging nor blood test results suggested pneumonia or other infections. Pulmonary arterial hypertension (PAH) was suspected on the basis of transthoracic echocardiography. PAH was then confirmed by right heart catheterization. Though dasatinib was discontinued on the day of hospitalization, pulmonary hypertension and heart failure progressed, and she did not respond to catecholamines or PDE5 (phosphodiesterase type 5) inhibitors. On the 4(th) hospital day, she experienced cardiopulmonary arrest and died 1 week later. Cases with PAH due to oral administration of dasatinib have been reported previously. However, cases showing the rapid progression documented in our patient are rare and we advocate that PAH be considered a potential adverse event associated with dasatinib therapy.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results